Stockscreener 앱 받기
45.87
1.76%
-0.82
시장 영업 전:
45.88
0.01
+0.02%
전일 마감가:
$46.69
열려 있는:
$46.37
하루 거래량:
3.83M
Relative Volume:
1.03
시가총액:
$19.65B
수익:
$2.35B
순이익/손실:
$1.30B
주가수익비율:
26.23
EPS:
1.7487
순현금흐름:
$1.05B
1주 성능:
+0.42%
1개월 성능:
+2.39%
6개월 성능:
+26.16%
1년 성능:
+39.63%
1일 변동 폭
$45.63
$46.49
1주일 범위
$44.94
$46.82
52주 변동 폭
$29.66
$47.86
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.87 | 19.65B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.13 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.61 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.85 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.23 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
285.30 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Magnetar Financial LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Experiences Valuation Adjustment Amidst Competitive Market Dynamics - Markets Mojo
The Bull Case For Royalty Pharma (RPRX) Could Change Following Asia Leadership Hire To Target Biotech Royalties - simplywall.st
WINTON GROUP Ltd Takes $3.36 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Capital International Investors Raises Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Capital International Sarl - MarketBeat
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 10th Largest Position - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Decreased by Rhenman & Partners Asset Management AB - MarketBeat
Neo Ivy Capital Management Buys New Position in Royalty Pharma PLC $RPRX - MarketBeat
Goodman Advisory Group LLC Purchases New Stake in Royalty Pharma PLC $RPRX - MarketBeat
CM Management LLC Takes $1.76 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.86 - Markets Mojo
Vera Therapeutics Appoints Christopher Hite to Board of Directors - GlobeNewswire Inc.
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Royalty Pharma Plc Hits New 52-Week High of USD 47.66 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Insider sales of common stock — Repare Therapeutics (NASDAQ: RPRX) - Stock Titan
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Victory Capital Management Inc. Purchases 165,727 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPRX Earnings History & Surprises | EPS & Revenue Results | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Royalty Pharma at TD Cowen Conference: Strategic Growth Insights - Investing.com Nigeria
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations - Yahoo Finance
RPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Royalty Pharma (RPRX) Passes Through 2% Yield Mark - Nasdaq
Royalty Pharma Plc Hits New 52-Week High of USD 46.37 - Markets Mojo
TD Asset Management Inc Acquires 91,136 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Quantbot Technologies LP Makes New $2.82 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 44,289 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule - Finviz
Royalty Pharma appoints Kenneth Sun to lead Asia expansion By Investing.com - Investing.com Australia
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform - Utusan Malaysia
Royalty Pharma Appoints Kenneth Sun as Senior VP and Head of Asia - National Today
Affiliated holders sell large RPRX stakes (RPRX) in Feb 2026 trades - Stock Titan
Royalty Pharma Plc (RPRX): Investor Outlook With 11.57% Upside Potential - DirectorsTalk Interviews
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks Q4 Earnings Call Highlights - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Royalty Pharma appoints Kenneth Sun to lead Asia expansion - Investing.com
Royalty Pharma Appoints Kenneth Sun as Senior Vice President - citybiz
Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026 - marketscreener.com
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
$250M cancer drug royalty deal extends Zymeworks’ cash runway - Stock Titan
Citigroup Inc. Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
RPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why - Finviz
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why - Insider Monkey
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
Royalty Pharma stock hits 52-week high at 46.14 USD By Investing.com - Investing.com Australia
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.48%
0.09%
자본화:
|
볼륨(24시간):